Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer
Forest plot of 5-year overall survival rates for RCTs and non-RCTs.
Primary Myelofibrosis (MF) Disease | Jakafi HCP
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer
Study shows survival benefits of smoking cessation after lung cancer diagnosis
survival - 5-year EFS > 5-year OS - Cross Validated
Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate
Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink
Breast Cancer Survival Rates: Prognosis by Age, Race & More
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports
Stereotactic ablative radiotherapy shows long-term benefit in operable early NSCLC
A Nomogram Predicting Overall and Cancer-Specific Survival of Patients with Primary Bone Lymphoma: A Large Population-Based Study
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
5-year Overall Survival Rates by Stage at Presentation | Download Scientific Diagram
Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram
This figure shows the 5-year overall survival (OS) in 250 synovial... | Download Scientific Diagram
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/4-Figure1-1.png "PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar")
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
